Recombinant Antibodies Network (RAN)

The Recombinant Antibody Network (RAN) is a multi-institutional research consortium (member institutions: The University of Toronto, University of California San Francisco and The University of Chicago) created accelerate the identification and development of recombinant antibodies raised against valuable and challenging targets to support drug development and cutting edge biomedical research.  The RAN was founded by three ex-Genentech antibody engineers.  To date the team has screened and validated over 880 antibodies, some of which are now available for licensing as therapeutics.

OPPORTUNITY

Program

Indication

Target Activity and Differentiating Features

Target Affinity

# Leads

RAN20-1

Multiple Myeloma Chronic Lymphocytic Leukemia

  • Antibody blocks binding of target ligand to receptor

NM

5

RAN20-2

Checkpoint inhibitor (Hematologic Malignancies, Breast, Glioblastoma, Renal Cancers)

  • Antibody blocks binding of target ligand to receptor
  • Induces phagocytosis of target tumor cells to a similar extent as clinical-stage antibodies in the same class

NM and Sub NM

2

RAN20-3

Same as RAN20-2

  • Upstream regulation of TNFa
  • Range of activities: some antibodies bind only to PBMCs and do not impact target ligand binding, others bind to both target ligand and PBMCs

Sub NM

6

RAN20-4

Immune suppressor specific to tumor microenvironment (Leukemia, Glioblastoma, Melanoma, Esophageal, Prostate, Ovarian, Breast Cancers)

  • ATP-mediated mechanism of binding to target
  • Similar molecules do not have ATP-mediated mechanism of binding, which targets this antibody specifically to the tumor microenvironment

NM (with ATP)

1

RAN20-5

K-Ras Mutations, Pancreatic Cancer

  • Binds to both full length and cleaved target antigen
  • Functional as an ADC and BiTE

Sub NM

1

COMPETITIVE ADVANTAGE

Phage display synthetic antibody libraries based on fully human frameworks and highly optimized for:

  • Good expression profile & high titers
  • Ease of production
  • Favorable toxicity profiles

Antibodies are extensively validated with a robust set of technical information available with antibody sequences and tangible material:

  • Cell binding assays
  • Kinetics (SPR)
  • Species cross reactivity (ELISA)
  • Epitope binning (ELISA)
  • HEK production (SDS-Page, SEC)

STATUS

  • IP:
    • Patent pending
  • Stage of Development:
    • Preclinical (LI/LO)

ID:

P1704

Keywords:

Antibodies , Cancer , Advanced Health Technologies , Biotechnology , Pharmaceuticals , Therapeutics